News & Events

Press Releases

Solid Biosciences to Participate at the Jefferies Healthcare Conference

June 2, 2022 at 8:00 AM EDT

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, Co-Founder and President, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET.

A live webcast will be available on the Company’s investor relations website, under the Events page accessible here: A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit

Investor Contact:
David Carey
FINN Partners

Media Contact:
Erich Sandoval
FINN Partners

Primary Logo

Source: Solid Biosciences Inc.